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S U M M A R Y
The Republic of Congo is on the World Health Organization (WHO) list of ‘high burden’ countries for
tuberculosis (TB) andHIV. TB is the leading cause of death amongHIV-infected patients in the Republic of
Congo. In this viewpoint, the available data on TB and HIV in the Republic of Congo are reviewed, and the
gaps and bottlenecks that the National TB Control Program (NTCP) faces are discussed. Furthermore,
priority requirements for developing and implementing TB and HIV collaborative service activities are
identiﬁed. HIV and TB control programs operate as distinct entities with separate case management
plans. The implementation of collaborative TB/HIV activities to evaluate andmonitor themanagement of
TB/HIV co-infected individuals remains inefﬁcient in most regions, and these activities are sometimes
non-existent. This reveals major challenges that require deﬁnition in order to improve the delivery of
healthcare. The NTCP lacks adequate resources for optimal implementation of control measures of TB
and HIV compliance and outcomes. The importance of aligning and integrating TB and HIV treatment
services (including follow-up) and adherence support services through coordinated and collaborative
efforts between individual TB and HIV programs is discussed. Aligning and integrating TB and HIV
treatment services through coordinated and collaborative efforts between individual TB and HIV
programs is required. However, the WHO recommendations are generic, and health services in the
Republic of Congo need to tailor their TB and HIV programs according to the availability of resources and
operational feasibility. This will also open opportunities for synergizing collaborative TB/HIV research
and training activities, which should be prioritized by the donors supporting the TB/HIV programs.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is now themost common cause of death from
infectious disease and remains a global emergency.1 An estimated* Corresponding author.
E-mail address: fntoumi@fcrm-congo.com (F. Ntoumi).
http://dx.doi.org/10.1016/j.ijid.2016.10.012
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).9.6 million new TB cases worldwide were reported by the World
Health Organization (WHO) in 2014. The WHO Africa Region had
more than twice the global average TB caseload, with 281 per 100
000 population. An estimated 1.2million out of the 9.6million new
caseswere HIV-positive, and Sub-Saharan Africa accounted for 74%
of these cases.1 The synergistic epidemics of HIV and TB have had a
devastating impact in high prevalence, resource-limited settings
such as Asia and Sub-Saharan Africa.2–4 Apart from socio-economicciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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relating to national TB and HIV programs, which continue to fuel
the TB epidemic in Sub-Saharan Africa.5
The Republic of Congo is considered a ‘high burden’ country for
TB andHIV infection.1,6,7 In this viewpoint article, current practices
in the management of patients within the Republic of Congo
national TB and HIV programs are described, and the gaps in
structural, functional, operational, and resource factors that need
priority attention are identiﬁed.
2. Need for more accurate data on TB and TB/HIV co-infection
in the Republic of Congo
In the Republic of Congo, the management of patients with TB
and HIV co-infection is associated with several diagnostic and
therapeutic challenges. HIV and TB control programs operate as
distinct entities with separate case management plans and
protocols. The implementation of collaborative TB/HIV activities
to evaluate and monitor the management of TB/HIV co-infected
individuals remains inefﬁcient inmost regions, and these activities
are non-existent in others. The Republic of Congo National TB
Control Program (NTCP) faces major operational and structural
issues and identifying these will help improve the development of
TB and HIV collaborative service activities. Despite the availability
of national diagnostic algorithms for TB diagnosis,8 making an
accurate diagnosis of patients with HIV/AIDS or TB or TB/HIV co-
infection is often delayed, resulting in high mortality rates.9
However, co-morbidity with other prevalent tropical diseases may
contribute to mortality and remains to be deﬁned (http://www.
msf.fr/pays/congo-brazzaville).
Available data show that in the Republic of Congo, the HIV
prevalence rate was 3.5% nationally, with peaks at 5% in urban
areas. HIV testing is not systematically performed among TB
patients and the actual prevalence of TB/HIV co-infection remains
unknown.9 In the Republic of Congo, there is no coordination
between the TB and HIV programs (. 1a) and there is no common
database or reporting system, which leads to separate reporting
and monitoring. In 2013, an estimated 69 000 people were living
with HIV infection, representing an HIV prevalence of about
2.5%;10,11 the incidence of TB in the Republic of Congo was 473 per
100 000 inhabitants (including TB/HIV co-infections), and 31% of
TB patients were HIV-positive.
3. The need for integrating TB and HIV care in the Republic of
Congo
TB is the leading cause of death in the Republic of Congo, killing
3000 people in 2014.1 No accurate data are available on the
number of people living with HIV in the Republic of Congo. From
the authors’ observations and small cohort studies, a signiﬁcant
proportion of people with TB appear to have HIV co-infection (out
of 1313 new TB patients tested for HIV, 29% were HIV-positive), as
is the case in other countries in Sub-Saharan Africa. There were
300 new cases with multidrug-resistant TB (MDR-TB) and the
number of reported retreatment cases with drug-resistant TB was
59 in 2014,1,9 although these are underestimates due to the lack of
widespread testing for MDR-TB.
Individuals with active TB or HIV disease or TB/HIV co-infection
will require careful investigation and management,12 with long-
term follow-up. The treatment drug regimens for both diseases
have to be taken daily, often have side effects, and may often be
incompatible.12,13 Thus it is vital that health care providers have
expertise and are trained with knowledge of recent WHO
guidelines on the treatment of all clinical forms of TB.12 WHO
recommendations are that people living with HIV (PLWHIV) be
routinely screened for TB, and as with non-HIV-associated TB, it isalso important that co-infection is addressed within the broader
WHO directly observed therapy (DOTS) framework. If an HIV-
positive person has a latent TB infection (LTBI), the WHO
recommends the provision of isoniazid preventive therapy
(IPT),14 which prevents the progression to active TB and has no
interactions with antiretroviral medication. IPT reduces the risk of
TB by 36% overall, and by 62% in HIV-infected people.1,12,14–16 A
study conducted in South Africa showed that the full integration of
TB and HIV care increased the chance of co-infected patients
starting antiretroviral therapy (ART) by 60%, and reduced the time
to ART initiation by an average of 72 days.17
4. Collaborations between TB and HIV national control
programs in Sub-Saharan Africa
International agencies, such as the WHO and the Joint United
Nations Programme on HIV/AIDS (UNAIDS), emphasize the
importance of a collaborative approach for health services to
tackle TB/HIV co-infection, including screening, testing, treatment,
and follow-up1,10,11 (Figure 1b). Opportunities for collaboration
between TB and HIV programs at the national level have been
taken forward to varying degrees in some African countries like
Malawi,18 Kenya,19 South Africa,20 Lesotho, Cameroon,21 and
Ethiopia,22 with signiﬁcant effects in some but not others. The
National TB and HIV control programs in the Republic of Congo are
regarded as two completely dissociated and unrelated programs.
As in the majority of Sub-Saharan African countries, adhering
strictly to WHO guidelines for collaborative TB/HIV activities
remains problematic,22–24,18 and the generic recommendations
may not ﬁt the requirements for all countries.25 The need for the
majority of Sub-Saharan African countries to reduce the burden of
TB signiﬁcantly in persons living with HIV/AIDS remains. WHO
guidelines for the treatment of patients at risk of developing active
TB, such as persons with HIV infection, recommend isoniazid-
based preventive treatment.14 These are not yet implemented fully
in the Republic of Congo. The diagnosis of pulmonary TB is
recommended, using an algorithm that is in use throughout the
country.8 Despite this, many cases of conﬁrmed pulmonary TB and
TB/HIV co-infection are diagnosed late or evenmissed, and cases of
false-negative smear are treated with a non-speciﬁc treatment.8
5. Current status quo, challenges, and bottlenecks of
establishing TB/HIV collaborative activities in the Republic of
Congo
The current status quo of the TB and HIV health programs and
their relationships in the Republic of Congo are outlined in
Figure 2. Although TB and antiretroviral treatments are subsidized
by the Republic of Congo government, disruptions in the supply
chain lead to treatment failure and resistance to these drugs.
Patients continue to be followed up at the TB center, and when HIV
is suspected, the TB patients are referred to the National HIV
Program for screening and management. There is no electronic
monitoring database for HIV or TB. Establishing quality integration
and implementation of TB/HIV services will address several priority
areas: the current low rates of TB screening and HIV testing,
insufﬁcient referral of TB patients for ART, and ongoing high TB
deaths among people with HIV and the low numbers on IPT.
In addition, the Republic of Congo TB/HIV healthcare services
face signiﬁcant resource and operational challenges.26 These
include limited stafﬁng, limited TB diagnostic methods, crowded
facilities, and poor infrastructure and resources. It should be
emphasized that inadequate infrastructure and stafﬁng are the
main challenges that play against the successful integration of TB
and HIV services in resource-constrained Republic of Congo. The
implementation of TB and HIV collaborative services will require
[(Figure_1)TD$FIG]
Figure 1. (a) Current TB and HIV program paradigms in the Republic of Congo. (b) Optimal TB and HIV program paradigms. (Adapted from Friedland et al.18).
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Figure 2. Relationships between the national HIV/AIDS and TB control programs in
the Republic of Congo.
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and careful tailoring of interventions is required for smoother
introduction into existing resource-constrained programs,
which are already overwhelmed with large numbers of patients.
Several important bottlenecks need to be overcome and aworkable
and feasible strategy developed for joint TB/HIV care in the
Republic of Congo.
5.1. Bottleneck 1: Poor case management
In the Republic of Congo, both HIV and TB national control
programs were created independently in terms of ﬁnance
allocation and management, logistics, and human resources.
Therefore, each program has its own agenda, including activities,
with no bridge between them. There are very few TB reference
centers in the country and the stock-out of HIV reagents and
medicines is quite common as well. Moreover, the management of
HIV supplies is not optimal, as sometimes reagents [3_TD$DIFF]close to [4_TD$DIFF]their
expiry date are delivered to health facilities. The casemanagement
[(Figure_3)TD$FIG]
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Figure 3. Full integration models of HIV/AIDS and TB national control programs.
Table 1
WHO policy for collaborative TB/HIV activities
ESTABLISH THE MECHANISMS FOR COLLABORATION
1. Ensure a coordinating body exists for effective TB/HIV collaboration at
all levels
2. Conduct surveillance of HIV prevalence among TB patients and TB
prevalence among HIV patients
3. Carry out joint HIV/TB planning
4. Conduct monitoring and evaluation
DECREASE THE BURDEN OF TB IN PEOPLE LIVING WITH HIV
5. Establish intensiﬁed TB case-ﬁnding
6. Introduce isoniazid prevention therapy
7. Ensure TB infection control in health care and congregate settings
DECREASE THE BURDEN OF HIV IN TB PATIENTS
8. Provide HIV testing and counseling
9. Introduce HIV prevention methods
DECREASE THE BURDEN FOR PEOPLE LIVING WITH HIV AND TB
10. Introduce co-trimoxazole prevention therapy
11. Ensure HIV and TB care and support
12. Provide antiretroviral therapy
WHO, World Health Organization; TB, tuberculosis.
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diagnostic and treatment tools.
5.2. Bottleneck 2: Poor health systems organization
Three major weakness points have been identiﬁed for the
implementation of an effective collaboration between TB and HIV
national control programs: (1) no coordination body for either
program, (2) no common surveillance studies, and (3) no joint TB/
HIV planning and actions. Referring to experience from other
countries, three service models have been rolled out so far: (1)
model of separate services for TB and HIV, (2) model of partial
collaboration using mixed model of referral of TB/HIV co-infected
patients,8,18,20 [2_TD$DIFF] and (3) model of full collaboration, a ‘one-stop’
service for TB, HIV, and TB/HIV co-infected patients.17,27,28 All of
these proposed collaborative models (Figure 3) were intended to
initiate collaboration and cooperation of the HIV and TB programs
and they have had varying degrees of success.
5.3. Bottleneck 3: Rapid diagnostic methods
A major obstacle in the ﬁght against TB is the lack of a cheap,
easy to use, rapid, and sensitivemethod to detect active TB in adults
and children in the community. More advanced methodologies
such as culture and PCR and the GeneXpert MTB/RIF assay29–31 are
not in widespread use in rural areas due to operational difﬁculties.
The Republic of Congo acquired GeneXpert equipment, which was
installed at the Centre Antituberculeux (CAT) in November 2013;
since then, the number of TB cases detected has been increasing.31
Unfortunately, the use of theGeneXpert is reserved only for patients
with pulmonary TB category II. In a recent study conducted in
Brazzaville, the number of HIV-positive cases detected was
increasing dramatically, and this led to the local authorities being
prompted to take urgent measures.3 The use of the urine
Lipoarabinomannan (LAM) LAM-ELISAmethod could improve rapid
screening for TB among HIV-infected individuals with advanced
immunosuppression,32[5_TD$DIFF] although these are declining in numbers
and the urine LAMmay stillmiss a large number of patientswith TB.
This rapid diagnostic technique is still not implemented in the
Republic of Congo, where the standard TB diagnostic technique
remains light microscopy.8
6. An appropriate model of TB/HIV collaboration, integration,
and implementation for the Republic of Congo
Rwanda has implemented a ‘one-stop TB/HIV service’ approach,
one of the strategies recommended by the WHO for collaborative
TB/HIV activities to address the burden of TB and HIV.33 As inRwanda, the Republic of Congo could improve the health system,
applying the early diagnosis and rapid initiation of treatment,
which remains a key strategy to control both HIV and TB. The ‘one-
stop TB service’ concept integrates new and existing diagnostic
technologies into a new ‘platform’ for use at the place where the
patient or risk group is, such as the point of care (POC). Under the
‘one-stop shop’ model, TB, HIV, and TB/HIV co-infected patients
are able to access a full package of services at one location,
managed by one health care worker or health care team. For
example, TB patients coming for TB treatment are offered HIV
counseling and testing, and HIV patients coming for ART are
routinely screened for TB. TB/HIV co-infected patients are able to
get both TB treatment and ART at once, from staff who are able to
more closely monitor their dual treatment outcomes.
7. Towards implementing TB and HIV collaborative service,
research, and training activities in the Republic of Congo
There are many challenges that need to be overcome in order to
synergize both TB and HIV national control programs in the
Republic of Congo and fulﬁll the WHO policy for the 12 collabora-
tive TB/HIV activities (Table 1). Capacity strengthening through the
provision of more stafﬁng resources with adequate salaries, along
with better training of health providers, is a priority. Improved
coordination between providers of TB care and providers of HIV
care in the Republic of Congo should lead to sharing of basic patient
information. IPT for HIV-infected adults (including pregnant
women) and children should be included in the HIV national
control program.34–36,15,16,37 In resource-poor Republic of Congo,
the current status quowill not allow formerger of the two separate
programs. Whilst such resources are being sought, immediate
priority areas for action are to increase communication and
collaboration between programs, and to establish joint research
and training activities. The Ministry of Public Health would play a
vital role in establishing and strengthening a coordinated approach
to both diseases and could follow the examples of other countries
who have established joint TB/HIV care programs.
Rwanda has set up TB/HIV collaboration at the central level
through the Ministry of Public Health (Figure 1b),33 whose
responsibility is to ensure that the directors of both programs
work in close collaboration, share human and ﬁnancial resources,
and do not duplicate efforts. In Rwanda, a study reported that TB
patients and staff at TB clinics were receptive to HIV testing. This
supports the premise that TB clinics could be an important point of
entry into life-saving HIV care and treatment services in Rwanda33
(Figure 3). The Republic of Congo could adopt this strategy to
L.S.G. Linguissi et al. / International Journal of Infectious Diseases 56 (2017) 62–6766enable the introduction of ART in outpatient treatment centers
dealing with TB. It could be important to begin implementing TB
services in HIV clinics and implementing HIV services in TB clinics.
This partial integration model of HIV service in the National TB
control program was tested in Swaziland and Cambodia; in these
countries there was a high coverage of co-trimoxazole preventive
therapy (CPT) and ART uptake in TB/HIV patients.38,39 In Malawi,
TB treatment is provided at TB ofﬁces and HIV testing is performed
at the separate HIV voluntary counseling and testing (VCT) units
based in the hospital. HIV-infected patients with TB are then
referred to the ART clinic for staging.18 The lack of a clear job
description including responsibilities for TB and HIV/AIDS control
program managers created tension and contributed to poor
implementation of joint TB/HIV activities in Uganda.40 The lack
of a common understanding of the concept of ‘integration’ was also
identiﬁed as a barrier that contributed to poor quality of services.41
In Rwanda and Kenya, implementation started using a ‘one-stop’
TB/HIV integrated services model (Figure 3),17,33,42,43 on the WHO
Three ‘I’s initiative (intensiﬁed TB case-ﬁnding, IPT, and infection
control).14,15
8. Financial support for HIV and TB national control programs
Over the past 10 years, the Global Fund has supported malaria,
tuberculosis, and HIV/AIDS programs in the Republic of Congo for
an amount totaling approximately 51 billion Central African
Francs.44 For 2015–2016, the Global Fund provided 16 156
313 Euros to support activities in six departments. However,
detailed reports on the national resource contributions to HIV and
TB activities in addition to those contributed by the Global Fund
are not available. An important need exists to develop a national
strategy for joint TB/HIV activities and present these to donor
agencies such as the Global Fund. Future Global Fund applications
could incorporate requests for funding to establish comprehensive
TB/HIV collaborative activities. These could then be aligned to
research and training activities, which are currently being rolled
out through competitive grant calls from the European Developing
Clinical Trials Partnerships.45
9. Conclusions
The Republic of Congo is on the WHO list of ‘high burden’
countries for TB and HIV, and TB is a very common cause of death
among the HIV-infected population. Available data on TB and HIV
from the Republic of Congo and collaborative TB/HIV activities are
scarce. There are major gaps and bottlenecks that the national TB
and HIV program staff face, and developing and implementing TB
and HIV collaborative service activities could lead to improve-
ments in TB/HIV care. Since the WHO recommendations are
generic, the Republic of Congo needs to perform a comprehensive
program review, identify synergies between TB and HIV/AIDS
services, and identify which collaborative model is best suited to
the Republic of Congo, which should be a priority for funding
agencies as well.
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